Pharmacist Medication Insights: Melphalan Flufenamide for Multiple Myeloma
Melphalan flufenamide (Pepaxto; melflufen) is approved for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.
In March, the
The approval was based on data from the phase 2 HORIZON study, which evaluated intravenous melphalan flufenamide in combination with dexamethasone. The multi-center, single arm study enrolled heavily pre-treated patients with a poor prognosis, which included 157 patients with relapsed/refractory multiple myeloma who had received 2 or more prior lines of therapy, were exposed to an immunomodulatory drug and a proteasome inhibitor, and were refractory to pomalidomide (Pomalyst) and/or daratumumab (Darzalex).
Participants had triple-class refractory disease and/or EMD and/or high-risk cytogenetic features. To be eligible for enrollment, patients had to have had an ECOG performance status of 0 to 2. Of those enrolled, 97 patients had triple-class refractory disease and had received at least 4 previous lines of treatment.
Study participants were given 40 mg of melphalan flufenamide on day 1 plus 40 mg of dexamethasone on days 1, 8, and 15. However, patients who were 75 years of age or older were given 20 mg of dexamethasone instead. Treatment was administered in 28-day cycles until either progressive disease or unacceptable toxicity.
The overall response rate (ORR) for patients in this group with refractory multiple myeloma was 23.7% and the median duration of response was 4.2 months. The results showed that melphalan flufenamide in combination with dexamethasone demonstrated activity in a subset of patients with extra medullary disease (41%), which is associated with a poor prognosis, according to the study authors.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025